Skip to main content
PharmaResearch Co., Ltd. logo

PharmaResearch Co., Ltd. — Investor Relations & Filings

Ticker · 214450 ISIN · KR7214450009 KO Manufacturing
Open in API
Filings indexed 261 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 214450

About PharmaResearch Co., Ltd.

https://pharmaresearch.co.kr/en/

PharmaResearch Co., Ltd. is a biopharmaceutical company specializing in regenerative medicine. It utilizes marine biotechnology to develop and commercialize refined raw materials for cell and tissue regeneration. The company's activities also encompass the manufacturing of medical devices and providing consulting services for the development, licensing, and registration of pharmaceuticals. PharmaResearch focuses on creating innovative biological products to enhance human health and quality of life.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 98% confidence The document is clearly a Korean 분기보고서 (quarterly report) covering the period 2026.01.01–2026.03.31 for PharmaResearch Co., Ltd. It includes detailed company overview, business description, capital changes, share issuance data, and substantive financial and non-financial disclosures. It is the full interim financial report itself, not merely an announcement or certification. This fits the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-05-15 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Interim / Quarterly Report Classification · 95% confidence The document is a Korean-language disclosure titled '연결재무제표 기준 영업(잠정)실적(공정공시)' which translates to 'Consolidated Financial Statements Based Operating (Preliminary) Results (Fair Disclosure)'. It provides financial results for the first quarter of 2026 (2026-01-01 to 2026-03-31) compared to previous quarters and the same period last year. The document includes detailed financial figures such as sales, operating profit, and net income, with percentage changes and notes that the figures are preliminary and unaudited. The length is 2904 characters, which is relatively short, but the document contains actual financial data and analysis, not just an announcement or a link to a report. It is not a full annual report but a quarterly or interim financial report with substantive financial data. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-08 Korean
기업설명회(IR)개최
Investor Presentation Classification · 95% confidence The document is titled '기업설명회(IR) 개최' which translates to 'Investor Relations (IR) Presentation Held'. It details the schedule, location, participants, purpose, and methods of an investor presentation event, including conference calls and meetings with analysts and institutional investors. The content focuses on the announcement and organization of an investor presentation rather than the presentation materials or detailed financial reports themselves. The document length is short (1202 characters) and it serves as an announcement of the event rather than the event content or financial data. Therefore, it fits the category of Investor Presentation (IP) as it is about the presentation event for investors focusing on financials and company strategy.
2026-05-06 Korean
결산실적공시예고
Report Publication Announcement Classification · 90% confidence The document is a short notice announcing the upcoming publication date for the company’s quarterly (1Q 2026) financial results rather than the results themselves. It provides the reporting period and the scheduled disclosure date, indicating it is an announcement of a forthcoming report. This matches the definition of a Report Publication Announcement (RPA).
2026-04-27 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 95% confidence The document is a mandatory disclosure to regulatory bodies (Korea Securities and Futures Commission and Korea Exchange) detailing the ownership status and share transactions by an officer (“임원”) of PharmaResearch (파마리서치), including the acquisition of 350 shares. This matches the definition of Director's Dealing (insider share transactions by executives).
2026-04-09 Korean
기업가치제고계획(자율공시)
Regulatory Filings Classification · 75% confidence The document is a Korean self-disclosed “기업가치 제고 계획” (corporate value enhancement plan) outlining future strategic targets (global expansion, M&A, dividend policy, etc.). It is not an AGM presentation, earnings release, financial report, proxy statement, or specific financing notice and does not attach a full report. It is a general regulatory announcement that does not neatly fit any other category. Therefore it falls into the fallback category “Regulatory Filings (RNS).”
2026-03-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.